Abstract
The coronavirus disease emerged in December 2019 (COVID-19) is caused
by Severe Acute Respiratory Syndrome-related coronavirus 2 (SARS-CoV-2). Its rapid
global spread has brought an international health emergency and urgent responses for
seeking efficient prevention and therapeutic treatment. This has led to imperative needs
for illustration of the molecular pathogenesis of SARS-CoV-2, identification of molecular
targets or receptors, and development of antiviral drugs, antibodies, and vaccines. In
this study, we investigated the current research progress in combating SARS-CoV-2
infection. Based on the published research findings, we first elucidated, at the molecular
level, SARS-CoV-2 viral structures, potential viral host-cell-invasion, pathogenic
mechanisms, main virus-induced immune responses, and emerging SARS-CoV-2
variants. We then focused on the main virus- and host-based potential targets and
summarized and categorized effective inhibitory molecules based on drug development
strategies for COVID-19 that can guide efforts for the identification of new drugs and
treatment for this problematic disease. Current research and development of antibodies
and vaccines were also introduced and discussed. We concluded that the main virus
entry route- SARS-CoV-2 spike protein interaction with ACE2 receptors played a key
role in guiding the development of therapeutic treatments against COVID-19. Four main
strategies may be considered in developing molecular therapeutics, and drug
repurposing is likely to be an easy, fast and low-cost approach in such a short period of
time with urgent need of antiviral drugs. Additionally, the quick development of antibody
and vaccine candidates has yielded promising results, but the wide-scale deployment of
safe and effective COVID-19 vaccines remains paramount in solving the pandemic
crisis. As new variants of the virus emerge, the efficacy of these vaccines and
treatments must be closely evaluated. Finally, we discussed the possible challenges of
developing molecular therapeutics for COVID-19 and suggested some potential future
efforts. Despite the limited availability of literature, our attempt in this work to provide a
relatively comprehensive overview of current SARS-CoV-2 studies can be helpful for
quickly acquiring the key information of COVID-19 and further promoting this important
research to control and diminish the pandemic.
Keywords:
SARS-CoV-2, COVID-19, viral molecules, potential targets, molecular inhibitors, antibodies, vaccines.
[3]
Baek YA-O, Um J, Antigua KJC, et al. Development of a reverse transcription-loop-mediated isothermal amplification as a rapid early-detection method for novel SARS-CoV-2. Emerg Microbes Infect 2020; 9(1): 998-1007.
[8]
Di Perri G. The rationale for low-molecular weight heparin (LMWH) use in SARS-CoV-2 infection. Infez Med 2020; 28: 52-6. 1124-9390.
[9]
U.S., F.D.A. FDA approves first treatment for COVID-19. 2020.
[11]
Du L, He Y, Zhou Y, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol 2009; 7(3): 226-36.
[17]
Yoshimoto FA-O. The proteins of severe acute respiratory syndrome coronavirus-2 (SARS CoV-2 or n-COV19), the cause of COVID-19. Protein J 2020; 39: 1875-8355.
[32]
Chellapandi P, Saranya S. Genomics insights of SARS-CoV- 2 (COVID-19) into target-based drug discovery. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents 2020; 1-15.
[39]
Fahmi M, Kubota Y, Ito M. Nonstructural proteins NS7b and NS8 are likely to be phylogenetically associated with evolution of 2019-nCoV. Infect Genet Evol 2020; 81: 1567-7257.
[63]
Cox RJ, Brokstad KA. Not just antibodies: B cells and T cells mediate immunity to COVID-19. Nat Rev Immunol 2020; 20: 1474-741. [Electronic]
[76]
Messerli FH, et al. Angiotensin-converting enzyme inhibitors in hypertension: To use or not to use? J Am Coll Cardiol 2018; 71: 1474-82. 1558-3597.
[81]
Kemp SA, Meng B. ATM Ferriera I, et al. Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70. bioRxiv 2021.
[83]
Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv 2021.
[100]
Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55: 1872-7913.
[106]
Gupta MA-O, Vemula S, Donde R, et al. In-silico approaches to detect inhibitors of the human severe acute respiratory syndrome coronavirus envelope protein ion channel. J Biomed Sci 2020; 15: 1538-0254.
[114]
Aranda-Abreu GE. Response to: Amantadine, COVID-19 and parkinsonism. Arch Med Res 2020; 51: 1873-5487.
[120]
Adem S, et al. Identification of potent COVID-19 main protease (Mpro) inhibitors from natural polyphenols: An in silico strategy unveils a hope against corona. MDPI AG 2020.
[122]
Hall DC Jr, Ji HF. A search for medications to treat COVID-19 viain silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis 2020; 35: 1873-0442.
[130]
Dastan F, et al. Thalidomide against coronavirus disease 2019 (COVID-19): A medicine with a thousand faces. Iran J Pharm Res 2020; 19: 1735-0328.
[155]
Fihn SD, Perencevich E, Bradley SM. Caution needed on the use of chloroquine and hydroxychloroquine for coronavirus disease 2019 pp. 2574-3805.
[184]
REICHERT J. Anti-SARS-CoV-2 antibody JS016 enters first clinical study. Antibody Society 2020
[192]
Zimmer JCC, Wee SL. Coronavirus vaccine tracker. The New York times 2020.